首页> 外文期刊>European journal of pharmaceutical sciences >Encapsulation and subsequent freeze-drying of Lactobacillus reuteri CRL 1324 for its potential inclusion in vaginal probiotic formulations
【24h】

Encapsulation and subsequent freeze-drying of Lactobacillus reuteri CRL 1324 for its potential inclusion in vaginal probiotic formulations

机译:罗伊氏乳杆菌CRL 1324的封装和随后的冻干,因为其潜在地包含在阴道益生菌制剂中

获取原文
获取原文并翻译 | 示例
           

摘要

Probiotic formulations must include a high number of viable and active microorganisms. In this work, the survival of human vaginal Lactobacillus reuteri CRL 1324 during encapsulation, lyophilization and storage, and the activity of encapsulated and/or freeze-dried bacterial cells were evaluated. Extrusion-ionic gelation technique was applied to encapsulate L. reuteri CRL 1324, using xanthan and gellan. Encapsulated and free bacterial cells were freeze-dried with or without lactose and skim milk as lyoprotectors. The different systems obtained were stored at room temperature and at 4 degrees C for 150 days. The following determinations were performed: L. reuteri CRL 1324 viability, microorganism released from capsules, survival in a medium simulating the vaginal fluid and maintenance of beneficial properties (growth inhibition of opportunistic pathogenic Streptococcus agalactiae NH 17 and biofilm formation). L. reuteri CRL 1324 encapsulation was efficient, allowing the recovery of a high number of entrapped lactobacilli. The survival of encapsulated L. reuteri during lyophilization and storage was significantly higher in the presence of lyoprotectors. At the end of storage, the highest numbers of viable cells were obtained in free or encapsulated cells freeze-dried with lyoprotectors, stored at 4 degrees C. Encapsulated and/or lyophilized L. reuteri cells maintained their viability in simulated vaginal fluid as well as the ability to inhibit S. agalactiae NH17 growth and to form biofilm. Encapsulated and freeze-dried L. reuteri CRL 1324 can be included in a suitable pharmaceutical form for vaginal application to prevent or treat urogenital infections in women. (C) 2015 Elsevier B.V. All rights reserved.
机译:益生菌制剂必须包含大量的活菌和活菌。在这项工作中,评估了人阴道罗伊氏乳杆菌CRL 1324在封装,冻干和储存过程中的存活率,以及封装和/或冻干的细菌细胞的活性。使用黄原胶和结冷胶,将挤出离子凝胶技术应用于罗伊氏乳杆菌CRL 1324的封装。在有或没有乳糖和脱脂乳作为冻干保护剂的情况下,将封装的游离细菌细胞冷冻干燥。将获得的不同系统在室温和4摄氏度下保存150天。进行了以下测定:罗伊氏乳杆菌CRL 1324的活力,从胶囊中释放的微生物,在模拟阴道液的培养基中的存活率和有益特性的维持(机会性病原性无乳链球菌NH 17的生长抑制和生物膜形成)。罗伊氏乳杆菌CRL 1324封装非常有效,可以回收大量被捕获的乳杆菌。在冻干保护剂的存在下,封装的罗伊氏乳杆菌在冻干和储存期间的存活率显着更高。储存结束时,在冻存的冻干的游离或包膜细胞中,在4摄氏度下保存的细胞数量最多。在模拟的阴道液中,经包囊和/或冻干的罗伊氏乳杆菌细胞保持活力。抑制无乳链球菌NH17生长并形成生物膜的能力。可以以适合的药物形式包括经封装和冻干的罗伊氏乳杆菌CRL 1324,用于阴道应用以预防或治疗女性泌尿生殖道感染。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号